The $300M Bet That Breathing Easier Starts in the Lungs

AP01 (inhaled pirfenidone) is furthest along, currently in a Phase 2b trial called MIST targeting progressive pulmonary fibrosis. Earlier Phase 1b data from the ATLAS trial in 91 patients showed the drug stabilized lung function over 48 weeks with notably fewer side effects than the oral version. Patients tolerated it well for up to 240 weeks in an open-label extension study. The Phase 2b readout will be a critical catalyst.

AP02 (inhaled nintedanib) is right behind. The Phase 2 AURA trial kicked off in March 2026, with the first patient already dosed. This randomized, placebo-controlled study is enrolling about 160 patients with idiopathic pulmonary fibrosis (IPF, the most common and severe form of the disease). Phase 1 data in IPF patients showed clean safety: no cough, no bronchospasm, no diarrhea.

AP03, the combination product, is still preclinical. The company has earmarked about $10 million to push it toward first-in-human studies.

Follow the Money

The IPO proceeds tell you exactly what Avalyn plans to do next. Roughly $150 million goes toward advancing AP01 into Phase 3. Another $90 million funds AP02's path to Phase 3. Combined with the $138.4 million already on the balance sheet heading into 2026, that's a war chest of approximately $440 million before the underwriters even exercise their option.

And about that option: Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities have 30 days to purchase an additional 2.5 million shares at the same $18 price, potentially adding another $45 million to the total.

This is a company that clearly doesn't want to come back to the market asking for more money anytime soon. Smart move in a market where dilution can kill momentum overnight.

Why Investors Showed Up Hungry

Avalyn's IPO didn't happen in a vacuum. The broader biotech IPO market in 2026 has been on a tear after a dismal stretch. In 2025, only about 10 U.S. biotechs went public. The window was barely cracked open.

This year, it's a different story. Analysts project 30 to 35 biotech IPOs for the full year, and the early entrants have been supersized. Eikon Therapeutics raised $381 million earlier in 2026. Agomab Therapeutics pulled in $200 million for its Nasdaq listing. Big pharma M&A has recycled cash back into the ecosystem, giving investors fresh capital to deploy.

Avalyn fits the profile that's winning right now: clinical-stage, scientifically differentiated, capital-efficient, and tackling real unmet medical needs. Smartkarma's IPO analytics platform gave the deal a 7.61 out of 10 overall.

The Risks Nobody's Ignoring

Before you start imagining Avalyn as a sure thing, let's talk about what could go wrong.

The Phase 2b data for AP01 has shown strong tolerability, but the lung function signals (measured by forced vital capacity, or FVC, the amount of air you can blow out) haven't been definitive yet. Tolerability is great. Proving your drug actually slows the disease better than existing options is the whole ballgame.

Then there's the adherence question. Oral pills are inconvenient, sure, but they're also simple. Avalyn's drugs require a nebulizer and 8 to 9 minutes per session, twice a day. For some patients, that trade-off will be worth it. For others, especially those without severe side effects on oral therapy, it might not be.

Finally, payers (insurance companies, Medicare) could demand patients try and fail oral antifibrotics before getting access to Avalyn's inhaled versions. That kind of step therapy requirement could limit the addressable market significantly unless the clinical data tells a compelling superiority story.

The Bottom Line

Avalyn Pharma just pulled off something rare: an IPO that was both oversized and priced at the top of the range, in a therapeutic area (rare lung disease) that doesn't exactly scream "retail investor hype." The company raised 50% more than it originally planned, and it did it on the strength of a genuinely clever scientific thesis.

The next 18 months will determine whether that thesis holds up. Topline data from both the MIST and AURA trials will either validate the $813 million valuation or expose it as premature optimism. For now, Avalyn has the cash, the clinical momentum, and clearly the investor confidence to find out.

Sometimes the best ideas in medicine aren't new molecules. They're better ways to deliver the ones we already have.

GSK Bet $700M on a Brain Theory. It Just Lost Twice.

GSK and Alector just killed their second Alzheimer's trial in six months, effectively torching a $700 million partnership. The failure raises uncomfortable questions about whether targeting the brain's immune system can actually slow neurodegeneration.